Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


13 Items
Title  Creator  Group name  Publishing year 
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer Desroys du Roure et al. EquipePM 2024-01-30
Anti-cathepsin D immunotherapy triggers both innate and adaptive anti-tumour immunity in breast cancer David et al. EquipePM 2023-11-29
SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity Alcaraz et al. EquipeELC 2022-11-08
Latent TGF-? Activation Is a Hallmark of the Tenascin Family Aubert et al. EquipeELC 2021
A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment Alcaraz et al. EquipeCTCS 2021
Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival Mansouri et al. EquipeCTCS 2020-05-15
BMP-1 disrupts cell adhesion and enhances TGF-? activation through cleavage of the matricellular protein thrombospondin-1 Anastasi et al. EquipeELC 2020-07-07
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies Ashraf et al. EquipeAT Feb 04, 2019
Acinar-to-Ductal Metaplasia Induced by Transforming Growth Factor Beta Facilitates KRASG12D-driven Pancreatic Tumorigenesis Chuvin et al. EquipeELC Sep 2017
TIF1? Suppresses Tumor Progression by Regulating Mitotic Checkpoints and Chromosomal Stability Pommier et al. EquipeELC Oct 15, 2015
Tenascin-X: beyond the architectural function Valcourt et al. EquipeELC 2015
Proteolytic control of TGF-? co-receptor activity by BMP-1/tolloid-like proteases revealed by quantitative iTRAQ proteomics Delolme et al. EquipeELC Mar 2015
Tenascin-X promotes epithelial-to-mesenchymal transition by activating latent TGF-? Alcaraz et al. EquipeELC May 12, 2014
13 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés